J. Goldman & Co LP acquired a new stake in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 68,232 shares of the company’s stock, valued at approximately $1,732,000. J. Goldman & Co LP owned 0.11% of Zenas BioPharma at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of ZBIO. Quarry LP raised its holdings in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Zenas BioPharma in the 3rd quarter valued at $30,000. Quantbot Technologies LP purchased a new stake in Zenas BioPharma in the second quarter valued at $49,000. BNP Paribas Financial Markets raised its position in Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares during the period. Finally, CWM LLC grew its holdings in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter.
Wall Street Analysts Forecast Growth
ZBIO has been the subject of several analyst reports. Morgan Stanley upped their price target on Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research note on Friday, August 14th. Zacks Research raised Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Finally, HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.71.
Zenas BioPharma Stock Performance
NASDAQ:ZBIO opened at $33.77 on Wednesday. The firm has a 50 day moving average of $28.84 and a 200-day moving average of $24.00. Zenas BioPharma, Inc. has a 1 year low of $13.50 and a 1 year high of $44.60. The stock has a market capitalization of $2.20 billion, a P/E ratio of -3.76 and a beta of -1.03. The company has a current ratio of 9.93, a quick ratio of 9.93 and a debt-to-equity ratio of 1.57.
Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million. As a group, sell-side analysts anticipate that Zenas BioPharma, Inc. will post -5.81 EPS for the current fiscal year.
Zenas BioPharma Profile
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Featured Stories
- Five stocks we like better than Zenas BioPharma
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
